Esperion Therapeutics (ESPR) PT Lowered to $69 at UBS; 'Buy' Maintained
Tweet Send to a Friend
UBS analyst Andrew Peters slashed his price target on Esperion Therapeutics (NASDAQ: ESPR) to $69.00 (from $133.00) but maintained a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
